Hosted on MSN3h
The New Gold Rush in Rare Disease Treatments and Merck KGaA’s Acquisition of SpringWorks Therapeutics
For many years, the pharmaceutical business concentrated mostly on blockbuster medications, which are cures for common ...
SpringWorks Therapeutics Inc (SWTX) Q4 2024 Earnings Report Preview: What To Expect
SpringWorks Therapeutics Inc (NASDAQ:SWTX) is set to release its Q4 2024 earnings on February 20, 2025. The consensus estimate for Q4 2024 revenue is $59.12 million, and the earnings are expected to ...
SpringWorks Therapeutics jumps after results, conference call cancellation
SpringWorks Therapeutics (NASDAQ:SWTX) jumped 10% in premarket trading after the firm reported its Q4 results and canceled ...
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively ...
SpringWorks Therapeutics reports FY24 EPS ($3.48), consensus ($3.16)
Reports FY24 revenue $191.5M, consensus $190.85M. “We are very pleased with the strong execution of OGSIVEO in 2024 and believe that we are ...
Why SpringWorks Therapeutics, Inc. (SWTX) is the Best Performing Healthcare Stock So Far in 2025
We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...
gritdaily2d
Merck KGaA and SpringWorks Therapeutics: The Rising Tide of Biotech M&A Amid High Valuations
The latest example of this trend is Merck KGaA’s impending all-cash acquisition of SpringWorks Therapeutics, valued around ...
Research Analysts Issue Forecasts for SWTX FY2024 Earnings
Stock analysts at HC Wainwright dropped their FY2024 earnings per share estimates for SpringWorks Therapeutics in a research note issued on Wednesday, February 12th. HC Wainwright analyst R. Burns now ...